Abilify Maintena (Aripiprazole Vials) 400mg

Abilify Maintena (aripiprazole) is an extended-release injectable antipsychotic used for schizophrenia and bipolar disorder maintenance. This 400mg vial formulation provides steady medication levels with once-monthly dosing. Ideal for long-term symptom management with professional supervision.

Strength

400mg

Pack Size

Storage

Ambient

Manufacturer / TM Owner

Otsuka Pharmaceutical Co. Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Aripiprazole 400mg extended-release injection is primarily used to treat schizophrenia and maintain stability in bipolar I disorder. It helps reduce symptoms like hallucinations, delusions, and mood swings by balancing dopamine and serotonin levels. This formulation is designed for patients stabilized on oral aripiprazole seeking convenient long-term therapy.

Side Effects

Patients may experience gradual symptom improvement over several weeks as the medication reaches steady levels. Common effects include reduced agitation and improved focus, though individual responses vary. The injectable form eliminates daily pill-taking while maintaining consistent drug exposure.

Precautions & Warnings

Store at room temperature away from moisture and heat. Keep out of reach of children and pets. Always handle vials carefully to prevent breakage. Discard any unused portion as directed by healthcare provider. Regular follow-ups are essential to monitor treatment progress.

Avoid Interactions

Avoid alcohol while using this medication as it may increase drowsiness. Certain medications like antidepressants, antifungals, or blood pressure drugs may interact with aripiprazole. Inform your doctor about all current medications before starting treatment. Grapefruit products can affect how the body processes this drug.

Frequently Asked Questions

Abilify Maintena is an extended-release injection used to treat schizophrenia and maintain stability in bipolar I disorder.

This medication is typically given once monthly by a healthcare professional.

Alcohol may increase drowsiness and should be avoided unless approved by your doctor.

Store at room temperature away from moisture and heat, and keep out of reach of children.

Contact your healthcare provider promptly to reschedule the injection.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.